NEJM· C. Michael Gibson P. Gabriel Steg M. Cecilia Bahit Rasha Al-Lamee Shamir R. Mehta Roxana Mehran Jeffrey I. Weitz Shinya Goto Jose Carlos Nicolau Renato D. Lopes Junbo Ge Nebojsa Tasic Dominick J. Angiolillo Suzanne J. Baron Ajay J. Kirtane Denis Xavier Satoshi Yasuda Basil S. Lewis Duk-Woo Park Jan H. Cornel Thomas W. Johnson Jaroslaw Trebacz Daniel Duerschmied Christoph Bode Bela Merkely Maria Dorobantu Dragos Vinereanu Zuzana Motovska Hector Bueno Jose Luis Lopez-Sendon Gregory Ducrocq Giuseppe Ambrosio Lesley Burgess Allan Bohm Chern-En Chiang Joao Morais Alan Fong Umit Guray Jose Luis Leiva-Pons Pascal Vranckx Harvey D. White Sasko Kedev Marco Valgimigli Duško Cerovec Dimitris Tousoulis Gemma Figtree Thuong Dung Ho Rody G. Sy Morten Bøttcher Kurt Huber Rimvydas Slapikas Andrejs Erglis Jack Wei Chieh Tan Christian Pincetti Karen S. Pieper Kenneth W. Mahaffey Carolyn S.P. Lam S. Claiborne Johnston Graeme J. Hankey Jennifer S. Li Luke Zheng Ronald Aronson Danshi Li Ravi Notani Philippe Vieira Pires Thomas J. Povsic Alistair C. Lindsay Alexei Plotnikov Hsiaowei Deng Elliot S. Barnathan and Robert A. Harringtonthe LIBREXIA ACS Committees and Investigators*·· 2026-08-29精选AI 评分62
NEJM 发表 milvexian 联合抗血小板治疗急性冠脉综合征的 III 期研究
Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event
AI 导读
NEJM 第 395 卷第 16 期发表 LIBREXIA ACS 研究，评估 milvexian 联合抗血小板治疗用于急性冠脉综合征事件后的患者，作者为 C. Michael Gibson、P. Gabriel Steg 等 LIBREXIA ACS 委员会与研究者。目前仅见摘要页信息，具体疗效与安全性数据需查阅原文。
推荐理由
NEJM 刊出 milvexian 联合抗血小板治疗用于 ACS 患者的 III 期研究，读者可据此了解该因子 XIa 抑制剂在这一人群中的评估结果。
来源：NEJM · nejm.org